MovDisordV3, Main, Exploration, bibRecord, 001313

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

Identifieur interne : 001313 ( Main/Exploration ); précédent : 001312; suivant : 001314

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

Auteurs : Vibeke Guldbrand Rasmussen [Danemark] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Steen Hvitfeldt Poulsen [Danemark]

Source :

Movement Disorders [ 0885-3185 ] ; 2011-04.

RBID : ISTEX:A3521F2ADEA85DDD6FC91814A070765A51D749C2

Descripteurs français

Pascal (Inist)
- Facteur risque, Fibrose, Homme, Insuffisance valvulaire, Maladie de Parkinson, Pathologie du système nerveux, Récepteur dopaminergique, Stimulant dopaminergique, Traitement, Valvule cardiaque.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Dopamine agonist, Dopamine receptor, Fibrosis, Heart valve, Human, Nervous system diseases, Parkinson, Parkinson disease, Risk factor, Treatment, Valvular regurgitation, dopamine agonist, ergolines, fibrosis, heart valve.

Abstract

Objectives:: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. Methods:: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated. Results:: The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure. Conclusions:: The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society

Url:

https://api.istex.fr/document/A3521F2ADEA85DDD6FC91814A070765A51D749C2/fulltext/pdf

DOI: 10.1002/mds.23470

Affiliations:

Danemark

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title>
<author><name sortKey="Rasmussen, Vibeke Guldbrand" sort="Rasmussen, Vibeke Guldbrand" uniqKey="Rasmussen V" first="Vibeke Guldbrand" last="Rasmussen">Vibeke Guldbrand Rasmussen</name>
</author>
<author><name sortKey=" Stergaard, Karen" sort=" Stergaard, Karen" uniqKey=" Stergaard K" first="Karen" last=" Stergaard">Karen  Stergaard</name>
</author>
<author><name sortKey="Dupont, Erik" sort="Dupont, Erik" uniqKey="Dupont E" first="Erik" last="Dupont">Erik Dupont</name>
</author>
<author><name sortKey="Poulsen, Steen Hvitfeldt" sort="Poulsen, Steen Hvitfeldt" uniqKey="Poulsen S" first="Steen Hvitfeldt" last="Poulsen">Steen Hvitfeldt Poulsen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A3521F2ADEA85DDD6FC91814A070765A51D749C2</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23470</idno>
<idno type="url">https://api.istex.fr/document/A3521F2ADEA85DDD6FC91814A070765A51D749C2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001D87</idno>
<idno type="wicri:Area/Istex/Curation">001D87</idno>
<idno type="wicri:Area/Istex/Checkpoint">000045</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Rasmussen V:the:risk:of</idno>
<idno type="wicri:Area/Main/Merge">001366</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0228424</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000613</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002705</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000351</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Rasmussen V:the:risk:of</idno>
<idno type="wicri:Area/Main/Merge">001941</idno>
<idno type="wicri:Area/Main/Curation">001313</idno>
<idno type="wicri:Area/Main/Exploration">001313</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists</title>
<author><name sortKey="Rasmussen, Vibeke Guldbrand" sort="Rasmussen, Vibeke Guldbrand" uniqKey="Rasmussen V" first="Vibeke Guldbrand" last="Rasmussen">Vibeke Guldbrand Rasmussen</name>
<affiliation wicri:level="1"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Cardiology, Aarhus University Hospital, Skejby</wicri:regionArea>
<wicri:noRegion>Skejby</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey=" Stergaard, Karen" sort=" Stergaard, Karen" uniqKey=" Stergaard K" first="Karen" last=" Stergaard">Karen  Stergaard</name>
<affiliation wicri:level="1"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Neurology, Aarhus University Hospital</wicri:regionArea>
<wicri:noRegion>Aarhus University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dupont, Erik" sort="Dupont, Erik" uniqKey="Dupont E" first="Erik" last="Dupont">Erik Dupont</name>
<affiliation wicri:level="1"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Neurology, Aarhus University Hospital</wicri:regionArea>
<wicri:noRegion>Aarhus University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poulsen, Steen Hvitfeldt" sort="Poulsen, Steen Hvitfeldt" uniqKey="Poulsen S" first="Steen Hvitfeldt" last="Poulsen">Steen Hvitfeldt Poulsen</name>
<affiliation wicri:level="1"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Cardiology, Aarhus University Hospital, Skejby</wicri:regionArea>
<wicri:noRegion>Skejby</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-04">2011-04</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="801">801</biblScope>
<biblScope unit="page" to="806">806</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">A3521F2ADEA85DDD6FC91814A070765A51D749C2</idno>
<idno type="DOI">10.1002/mds.23470</idno>
<idno type="ArticleID">MDS23470</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Fibrosis</term>
<term>Heart valve</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson</term>
<term>Parkinson disease</term>
<term>Risk factor</term>
<term>Treatment</term>
<term>Valvular regurgitation</term>
<term>dopamine agonist</term>
<term>ergolines</term>
<term>fibrosis</term>
<term>heart valve</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Facteur risque</term>
<term>Fibrose</term>
<term>Homme</term>
<term>Insuffisance valvulaire</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Récepteur dopaminergique</term>
<term>Stimulant dopaminergique</term>
<term>Traitement</term>
<term>Valvule cardiaque</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objectives:: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. Methods:: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated. Results:: The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure. Conclusions:: The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Danemark</li>
</country>
</list>
<tree><country name="Danemark"><noRegion><name sortKey="Rasmussen, Vibeke Guldbrand" sort="Rasmussen, Vibeke Guldbrand" uniqKey="Rasmussen V" first="Vibeke Guldbrand" last="Rasmussen">Vibeke Guldbrand Rasmussen</name>
</noRegion>
<name sortKey=" Stergaard, Karen" sort=" Stergaard, Karen" uniqKey=" Stergaard K" first="Karen" last=" Stergaard">Karen  Stergaard</name>
<name sortKey="Dupont, Erik" sort="Dupont, Erik" uniqKey="Dupont E" first="Erik" last="Dupont">Erik Dupont</name>
<name sortKey="Poulsen, Steen Hvitfeldt" sort="Poulsen, Steen Hvitfeldt" uniqKey="Poulsen S" first="Steen Hvitfeldt" last="Poulsen">Steen Hvitfeldt Poulsen</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001313 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001313 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A3521F2ADEA85DDD6FC91814A070765A51D749C2
   |texte=   The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.